Moffitt Cancer Center | Strategic Alliance Partners

January 04, 2024

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

January 03, 2024

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

January 02, 2024

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

January 02, 2024

Experts on follicular lymphoma discuss second-line treatment options available for patients.

January 02, 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

December 19, 2023

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

December 18, 2023

Experts on follicular lymphoma discuss first-line treatment options available for patients.

December 15, 2023

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

November 15, 2023

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.

November 07, 2023

Arnold Etame, MD, PhD, discusses the effects of a patient’s socioeconomic status on the cancer treatment options they receive.

November 02, 2023

Andrew T. Kuykendall, MD, discusses the importance of the approval of momelotinib in the treatment of patients with anemic symptomatic myelofibrosis, key efficacy and safety data from the MOMENTUM trial that supported the decision, and unanswered questions regarding the agent’s potential role in other subsets within this population.

October 24, 2023

Danielle K. DePalo, MD, explains the lack of research directly comparing first-line treatment options for patients with unresectable melanoma in-transit metastases, expands on the safety and efficacy of 3 treatment modalities for these patients, and underscores the need for more data to inform the management of these patients.

October 21, 2023

Andrew Kuykendall, MD, discusses frontline cytoreductive treatment options for patients with polycythemia vera.

October 16, 2023

Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.

October 12, 2023

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

October 12, 2023

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

October 05, 2023

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

October 05, 2023

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

September 28, 2023

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

September 28, 2023

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.